Monitor upcoming catalysts: Q2 2026 presentation of full Phase 2 AvailTM data for canvuparatide, Phase 2a STEADI™ results for imapextide, and candidate nominations in obesity pipeline. The cash runway into 2029 reduces near-term dilution risk.
Price Chart
Executive Summary
MBX Biosciences reported its Q4 and full-year 2025 financial results, highlighted by a strengthened balance sheet with $459.1 million in pro forma cash following an $85.4 million ATM raise, advancing its clinical pipeline including a planned Phase 3 trial for once-weekly canvuparatide in hypoparathyroidism (Q3 2026), and progressing obesity candidates MBX 4291 and new triple-agonist programs. Despite increased R&D and G&A spending driving a wider net loss, the company is well-funded into 2029.
Key Financial Metrics
Key Facts
- Completed End-of-Phase 2 FDA meeting for once-weekly canvuparatide; Phase 3 trial initiation on track for Q3 2026
- EU Orphan Drug Designation granted for canvuparatide
- Raised $85.4 million in net proceeds via ATM in February 2026, bringing pro forma cash to $459.1 million as of Dec 31, 2025
- Cash runway expected to fund operations into 2029
- Net loss for full year 2025 was $87.0 million vs. $61.9 million in 2024
- Appointed Laurie Stelzer to Board and Audit Committee Chair, and Karen Basbaum as Chief Business Officer
- 12-week Phase 1 data for MBX 4291 (obesity) expected in Q4 2026; amycretin and triple-agonist candidates to be nominated in Q2 and Q3 2026
Financial Impact
Increased R&D and G&A expenses drove a 40% YoY increase in net loss to $87.0 million, but cash position grew to $459.1 million pro forma, supporting operations into 2029
Risk Factors
- Clinical development risks in advancing canvuparatide to Phase 3 and MBX 4291 through Phase 1
- Increasing net losses and reliance on successful clinical execution to justify valuation
- Forward-looking statements subject to regulatory, development, and funding risks as outlined in SEC filings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254562 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 3 | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Oct 22, 2026 4d ago | 8-K | $50.46 $48.50 | ▼ −3.88% | ▼ −3.36% | $50.29 (−0.34%) |
Aug 27, 2026 8w ago | Press Release | $66.39 $63.00 | ▼ −5.11% | ▼ −4.88% | $50.29 (−24.25%) |
Aug 17, 2026 10w ago | 144 | $68.25 $66.52 | ▼ −2.53% | ▼ −1.86% | $50.29 (−26.32%) |
Aug 6, 2026 11w ago | 8-K | $67.11 $67.82 | ▲ +1.06% | ▲ +0.45% | $50.29 (−25.06%) |
Jun 12, 2026 19w ago | 8-K | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 12, 2026 19w ago | Press Release | $35.51 $38.98 | ▲ +9.77% | ▲ +8.01% | $50.29 (+41.62%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $37.25 $35.51 | ▼ −4.67% | ▼ −5.21% | $50.29 (+35.01%) |
Jun 10, 2026 19w ago | 144 | $30.99 $37.25 | ▲ +20.20% | ▲ +18.50% | $50.29 (+62.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers